Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
S-Biomedic NV is active in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This matter is located in 1 distinct art unit, suggesting a specific focus for its current biological research filings. The presence of this single matter indicates a highly targeted approach to its current patent prosecution within the biotechnology sector.
The prosecution is handled by 1 distinct examiner, MONSHIPOURI, MARYAM. As the busiest examiner for the company, MONSHIPOURI, MARYAM is managing 1 pending office action. This profile shows a concentrated interaction with the patent office, involving a single individual and one specific art unit for the company's current pharmaceutical portfolio. For practitioners, this means that the company's current standing in the Biotechnology & Pharmaceuticals area is entirely dependent on the review of this examiner.
The alignment of the pending office action with 1 distinct examiner and 1 distinct art unit reflects a streamlined prosecution footprint. This structure may allow for a more consistent dialogue between the applicant and the office, as there are no competing matters across different examiners or units. The focus on Biotechnology & Pharmaceuticals ensures that the prosecution remains within a specialized technical domain.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONSHIPOURI, MARYAM | 1 | 79.2% | +37.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18728031 | SKIN CARE COMPOSITION AND USES THEREOF | MONSHIPOURI, MARYAM | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18728031 | SKIN CARE COMPOSITION AND USES THEREOF | MONSHIPOURI, MARYAM | 1651 | §112DP | Non-Final OA | — | Pending | Jul 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialS-Biomedic NV has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maryam Monshipouri has the most, with 1 of S-Biomedic NV's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
